Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL

Partner | Cancer Centers | <b>SCCA</b>

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the methods utilized in an ongoing phase 1/2 trial (NCT03277729) evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL).

The study enrolled patients with CD20-positive B-NHL, Shadman says. Moreover, each histology had specific eligibility criteria that varied for high-grade vs low-grade lymphomas vs CLL, Shadman explains. Overall, if patients expressed the CD20 target, they were considered eligible for enrollment, Shadman says.

Moreover, patients underwent biopsies was required to biopsy patients both before and after infusion. Otherwise, the study schema was similar to that observed in the clinical trials evaluating CD19-directed CAR T-cell therapies, Shadman continues. Additionally, MB-106 is given as an outpatient therapy. Excluding the first patient treated in each dose cohort, patients received MB-106 in the outpatient setting, Shadman concludes.